Nucleophosmin as a candidate prognostic biomarker of ewing's sarcoma revealed by proteomics

Kazutaka Kikuta, Naobumi Tochigi, Tadakazu Shimoda, Hiroki Yabe, Hideo Morioka, Yoshiaki Toyama, Ako Hosono, Yasuo Eppu, Akira Kawai, Setsuo Hirohashi, Tadashi Kondo

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Purpose: We aimed to identify novel prognostic biomarkers for Ewing's sarcoma by investigating the global protein expression profile of Ewing's sarcoma patients. Experimental Design: We examined the proteomic profile of eight biopsy samples from Ewing's sarcoma patients using two-dimensional difference gel electrophoresis. Three patients were alive and continuously disease-free over 3 years after the initial diagnosis (good prognosis group) and five had died of the disease within 2 years of the initial diagnosis (poor prognosis group). Results: The protein expression profiles produced using two-dimensional difference gel electrophoresis consisted of 2,364 protein spots, among which we identified 66 protein spots whose intensity showed >2-fold difference between the two patient groups. Mass spectrometric protein identification showed that the 66 spots corresponded to 53 distinct gene products. Pathway analysis revealed that 31 of 53 proteins, including nucleophosmin, were significantly related to bone tissue neoplasms (P < 0.000001). The prognostic performance of nucleophosmin was evaluated immunohistochemically on an additional 34 Ewing's sarcoma cases. Univariate and multivariate analyses revealed that nucleophosmin expression significantly correlated with overall survival (P < 0.01). Conclusions: These results establish nucleophosmin as a candidate of independent prognostic marker for Ewing's sarcoma patients. Measuring nucleophosmin in biopsy samples before treatment may contribute to the effective management of Ewing's sarcoma.

Original languageEnglish
Pages (from-to)2885-2894
Number of pages10
JournalClinical Cancer Research
Volume15
Issue number8
DOIs
Publication statusPublished - 2009 Apr 15

Fingerprint

Ewing's Sarcoma
Proteomics
Biomarkers
Two-Dimensional Difference Gel Electrophoresis
Proteins
Bone Tissue Neoplasms
Biopsy
nucleophosmin
Research Design
Multivariate Analysis
Survival
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kikuta, K., Tochigi, N., Shimoda, T., Yabe, H., Morioka, H., Toyama, Y., ... Kondo, T. (2009). Nucleophosmin as a candidate prognostic biomarker of ewing's sarcoma revealed by proteomics. Clinical Cancer Research, 15(8), 2885-2894. https://doi.org/10.1158/1078-0432.CCR-08-1913

Nucleophosmin as a candidate prognostic biomarker of ewing's sarcoma revealed by proteomics. / Kikuta, Kazutaka; Tochigi, Naobumi; Shimoda, Tadakazu; Yabe, Hiroki; Morioka, Hideo; Toyama, Yoshiaki; Hosono, Ako; Eppu, Yasuo; Kawai, Akira; Hirohashi, Setsuo; Kondo, Tadashi.

In: Clinical Cancer Research, Vol. 15, No. 8, 15.04.2009, p. 2885-2894.

Research output: Contribution to journalArticle

Kikuta, K, Tochigi, N, Shimoda, T, Yabe, H, Morioka, H, Toyama, Y, Hosono, A, Eppu, Y, Kawai, A, Hirohashi, S & Kondo, T 2009, 'Nucleophosmin as a candidate prognostic biomarker of ewing's sarcoma revealed by proteomics', Clinical Cancer Research, vol. 15, no. 8, pp. 2885-2894. https://doi.org/10.1158/1078-0432.CCR-08-1913
Kikuta, Kazutaka ; Tochigi, Naobumi ; Shimoda, Tadakazu ; Yabe, Hiroki ; Morioka, Hideo ; Toyama, Yoshiaki ; Hosono, Ako ; Eppu, Yasuo ; Kawai, Akira ; Hirohashi, Setsuo ; Kondo, Tadashi. / Nucleophosmin as a candidate prognostic biomarker of ewing's sarcoma revealed by proteomics. In: Clinical Cancer Research. 2009 ; Vol. 15, No. 8. pp. 2885-2894.
@article{ec4df53dda91442e935d9ae320326016,
title = "Nucleophosmin as a candidate prognostic biomarker of ewing's sarcoma revealed by proteomics",
abstract = "Purpose: We aimed to identify novel prognostic biomarkers for Ewing's sarcoma by investigating the global protein expression profile of Ewing's sarcoma patients. Experimental Design: We examined the proteomic profile of eight biopsy samples from Ewing's sarcoma patients using two-dimensional difference gel electrophoresis. Three patients were alive and continuously disease-free over 3 years after the initial diagnosis (good prognosis group) and five had died of the disease within 2 years of the initial diagnosis (poor prognosis group). Results: The protein expression profiles produced using two-dimensional difference gel electrophoresis consisted of 2,364 protein spots, among which we identified 66 protein spots whose intensity showed >2-fold difference between the two patient groups. Mass spectrometric protein identification showed that the 66 spots corresponded to 53 distinct gene products. Pathway analysis revealed that 31 of 53 proteins, including nucleophosmin, were significantly related to bone tissue neoplasms (P < 0.000001). The prognostic performance of nucleophosmin was evaluated immunohistochemically on an additional 34 Ewing's sarcoma cases. Univariate and multivariate analyses revealed that nucleophosmin expression significantly correlated with overall survival (P < 0.01). Conclusions: These results establish nucleophosmin as a candidate of independent prognostic marker for Ewing's sarcoma patients. Measuring nucleophosmin in biopsy samples before treatment may contribute to the effective management of Ewing's sarcoma.",
author = "Kazutaka Kikuta and Naobumi Tochigi and Tadakazu Shimoda and Hiroki Yabe and Hideo Morioka and Yoshiaki Toyama and Ako Hosono and Yasuo Eppu and Akira Kawai and Setsuo Hirohashi and Tadashi Kondo",
year = "2009",
month = "4",
day = "15",
doi = "10.1158/1078-0432.CCR-08-1913",
language = "English",
volume = "15",
pages = "2885--2894",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Nucleophosmin as a candidate prognostic biomarker of ewing's sarcoma revealed by proteomics

AU - Kikuta, Kazutaka

AU - Tochigi, Naobumi

AU - Shimoda, Tadakazu

AU - Yabe, Hiroki

AU - Morioka, Hideo

AU - Toyama, Yoshiaki

AU - Hosono, Ako

AU - Eppu, Yasuo

AU - Kawai, Akira

AU - Hirohashi, Setsuo

AU - Kondo, Tadashi

PY - 2009/4/15

Y1 - 2009/4/15

N2 - Purpose: We aimed to identify novel prognostic biomarkers for Ewing's sarcoma by investigating the global protein expression profile of Ewing's sarcoma patients. Experimental Design: We examined the proteomic profile of eight biopsy samples from Ewing's sarcoma patients using two-dimensional difference gel electrophoresis. Three patients were alive and continuously disease-free over 3 years after the initial diagnosis (good prognosis group) and five had died of the disease within 2 years of the initial diagnosis (poor prognosis group). Results: The protein expression profiles produced using two-dimensional difference gel electrophoresis consisted of 2,364 protein spots, among which we identified 66 protein spots whose intensity showed >2-fold difference between the two patient groups. Mass spectrometric protein identification showed that the 66 spots corresponded to 53 distinct gene products. Pathway analysis revealed that 31 of 53 proteins, including nucleophosmin, were significantly related to bone tissue neoplasms (P < 0.000001). The prognostic performance of nucleophosmin was evaluated immunohistochemically on an additional 34 Ewing's sarcoma cases. Univariate and multivariate analyses revealed that nucleophosmin expression significantly correlated with overall survival (P < 0.01). Conclusions: These results establish nucleophosmin as a candidate of independent prognostic marker for Ewing's sarcoma patients. Measuring nucleophosmin in biopsy samples before treatment may contribute to the effective management of Ewing's sarcoma.

AB - Purpose: We aimed to identify novel prognostic biomarkers for Ewing's sarcoma by investigating the global protein expression profile of Ewing's sarcoma patients. Experimental Design: We examined the proteomic profile of eight biopsy samples from Ewing's sarcoma patients using two-dimensional difference gel electrophoresis. Three patients were alive and continuously disease-free over 3 years after the initial diagnosis (good prognosis group) and five had died of the disease within 2 years of the initial diagnosis (poor prognosis group). Results: The protein expression profiles produced using two-dimensional difference gel electrophoresis consisted of 2,364 protein spots, among which we identified 66 protein spots whose intensity showed >2-fold difference between the two patient groups. Mass spectrometric protein identification showed that the 66 spots corresponded to 53 distinct gene products. Pathway analysis revealed that 31 of 53 proteins, including nucleophosmin, were significantly related to bone tissue neoplasms (P < 0.000001). The prognostic performance of nucleophosmin was evaluated immunohistochemically on an additional 34 Ewing's sarcoma cases. Univariate and multivariate analyses revealed that nucleophosmin expression significantly correlated with overall survival (P < 0.01). Conclusions: These results establish nucleophosmin as a candidate of independent prognostic marker for Ewing's sarcoma patients. Measuring nucleophosmin in biopsy samples before treatment may contribute to the effective management of Ewing's sarcoma.

UR - http://www.scopus.com/inward/record.url?scp=65349144856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65349144856&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-08-1913

DO - 10.1158/1078-0432.CCR-08-1913

M3 - Article

C2 - 19351769

AN - SCOPUS:65349144856

VL - 15

SP - 2885

EP - 2894

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 8

ER -